Intelligence · Patents
Expiring patents (≤12 months)
Patent cliff watchlist — pharmaceutical patents approaching loss of exclusivity.
- Patents
- 11
Quick answer
11 pharmaceutical patents in our index expire within the next 12 months. Use year facets below for annual patent-cliff planning linked to company and drug profiles.
-
US 7087591
21-substituted progesterone derivatives as new antiprogestational agents
granted -
US 7122624
Parathyroid hormone receptor ligands
granted -
US 7126008
Carvedilol
granted -
US 7138137
Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
granted -
US 7148376
Polymorphic forms of nateglinide
granted -
US 7183272
Crystal forms of oxcarbazepine and processes for their preparation
granted -
US 7196222
Sertraline hydrochloride form II and methods for the preparation thereof
granted -
US 7196205
Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
granted -
US 7199157
Use of treprostinil to improve kidney functions
granted -
US 7235691
Crystalline forms of modafinil
granted -
US 7247751
Processes for preparing cinacalcet hydrochloride crystal Form I
granted
Frequently asked questions
What is a patent cliff?
A patent cliff is when key pharmaceutical patents expire, opening markets to generics or biosimilars. This hub lists USPTO patents with approaching expiration dates.
Are expiration dates estimates?
Expiration dates derive from USPTO PatentsView grant dates and term estimates. Confirm with Orange Book, patent counsel, and USPTO records before investment decisions.